Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96547e853272614b80b1cabdf8528041 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate |
2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c629cbba2784577109f4a88d608dcf8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f377e1f6c9df85c65341dafd08fdd723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82d642f32ad0cd7c68a92a9f82c38e17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9acc1de2b9c4fb3849a576c82f4796 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3f7052ecefdfebc9a88a95e48ef978e |
publicationDate |
2021-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-113862369-A |
titleOfInvention |
Markers related to the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy and their applications |
abstract |
The invention discloses markers related to the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy and applications thereof. The markers include miR-3202, miR-3663-3p, and/or miR-449a. When the marker is used to predict the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy, it has high diagnostic efficiency. The present invention provides a new direction for the selection of clinical treatment methods for patients with lung adenocarcinoma, and has better diagnostic performance. prospects for clinical application. |
priorityDate |
2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |